Trilaciclib, an intravenous CDK 4/6 inhibitor, in combination with Hycamtin may reduce chemotherapy-induced myelosuppression in small cell lung cancer, according to one expert.
Dr. Lowell Hart
Advertisement
Articles by Dr. Lowell Hart
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Jemperli for dMMR Locally Advanced Rectal Cancer
2
New Myelofibrosis Guidelines Back Wider Gene Testing at Diagnosis
3
Gemcitabine Plus BCG Clears Bladder Cancer in 96% of Patients After BCG Failure
4
FDA Clears AI Tool Using MRI to Gauge Breast Cancer Recurrence
5